<DOC>
	<DOCNO>NCT00005878</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . Celecoxib may effective prevent cancer patient Barrett 's esophagus . PURPOSE : Randomized phase II trial study effectiveness celecoxib prevent cancer patient Barrett 's esophagus .</brief_summary>
	<brief_title>Celecoxib Prevent Cancer Patients With Barrett 's Esophagus</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety efficacy celecoxib regression Barrett 's dysplasia patient low high-grade dysplasia esophagus . OUTLINE : This randomize , parallel , double-blind , placebo-controlled , multicenter study . Patients stratify accord center grade dysplasia baseline ( low vs high ) . Patients randomize one two treatment arm . - Arm I : Patients receive oral celecoxib twice daily 48-96 week . - Arm II : Patients receive oral placebo arm I . Treatment continue arm absence unacceptable toxicity development adenocarcinoma esophagus cancer site . Patients follow 12 week . PROJECTED ACCRUAL : A total 200 patient ( 100 per arm ) accrue study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Barrett 's dysplasia specific information location ( level ) high grade dysplasia base biopsy baseline endoscopy Short segment Barrett 's esophagus must sufficient area allow biopsy without complete resection No presence reflux esophagitis grade 24 No history confirm invasive carcinoma esophagus No diagnosis esophageal , gastric , pyloric channel , duodenal ulceration 1 cm diameter within past 30 day PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Hemoglobin least 9 g/dL Platelet count great 125,000/mm^3 WBC great 3,000/mm^3 No significant bleed disorder No abnormal hematopoietic laboratory test result would preclude study Hepatic : PT/PTT great 1.5 time upper limit normal ( ULN ) AST/ALT le 1.5 time ULN Alkaline phosphatase less 1.5 time ULN No chronic acute hepatic disorder No abnormal hepatic laboratory test result would preclude study Renal : Creatinine great 1.5 time ULN No chronic acute renal disorder No abnormal renal laboratory test result would preclude study Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior concurrent active inflammatory bowel disease ( e.g. , Crohn 's disease ulcerative colitis ) No prior concurrent curatively treated malignancy survival prognosis le 5 year No hypersensitivity adverse reaction COX2 inhibitor ( e.g. , celecoxib ) , sulfonamide , salicylate , NSAIDs No significant medical , psychological , psychosocial condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : At least 6 month since prior regular ( least 2 week duration ) oral intravenous corticosteroid At least 6 month since prior regular ( least 4 week duration ) inhale corticosteroid No concurrent regular oral intravenous corticosteroid No concurrent regular inhale corticosteroid Concurrent corticosteroid nasal spray allow Radiotherapy : At least 12 week since prior radiotherapy chest upper abdomen Surgery : At least 3 month since prior surgery esophagus stomach except hiatal hernia repair , fundoplication , vagotomy , pyloroplasty No prior complete mucosal resection use technique No concurrent resection highgrade nodule Other : At least 30 day since prior chronic ( least 3 time week great 2 week ) aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) ( i.e. , great 100 mg/day ) No prior complete mucosal ablation use technique No prior treatment study At least 30 day since prior investigational medication include shingle vaccine No concurrent chronic NSAIDs COX2 inhibitor except lowdose aspirin ( i.e. , great 100 mg/day ) No concurrent anticoagulant ( e.g. , heparin warfarin ) No concurrent investigational medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>esophageal cancer</keyword>
</DOC>